The LiBBY trial tested an oral THC/CBD combination for agitation in people with advanced dementia, and it found a real benefit alongside a real safety signal. Participants on the drug had roughly double the rate of serious adverse events compared with placebo, even as their agitation scores improved more than the placebo group's did. That combination — meaningful benefit and a clear increase in serious adverse events — is exactly what families weighing research participation for a relative with memory loss need to understand before they say yes to a similar study.
The trial, a Phase 2, 12-week, randomized, placebo-controlled study of a formulation called T2:C100, enrolled 120 adults with advanced dementia across multiple U.S. academic sites, according to the Alzheimer's Association International Conference. Its results raise practical questions for anyone asked to enroll a loved one, or themselves, in a dementia drug trial.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the LiBBY trial actually find?
- Who was actually eligible, and why that matters for your relative
- Why consent worked differently in this trial
- How the trial was run and funded
- What's still missing before drawing firm conclusions
- Frequently Asked Questions
What did the LiBBY trial actually find?
Researchers presenting at AAIC in July 2026 reported that participants taking the THC/CBD formulation had an 8.23-point greater reduction in Cohen-Mansfield Agitation Inventory scores than those on placebo at week 12, meeting the trial's main efficacy goal, according to AAIC. The Cohen-Mansfield Agitation Inventory is a standard tool clinicians use to rate how often and how severely a person shows behaviors like pacing, resisting care, or verbal outbursts. The safety picture moved in the opposite direction.
Serious adverse events occurred in 23.3% of participants on the THC/CBD formulation versus 11.9% on placebo — close to double — even though overall adverse event rates, which were mostly non-serious reactions, were similar between the two groups at 46.7% and 42.4%, according to NeurologyLive. Trial investigators attributed none of the serious adverse events in the treatment group to the study drug, but that judgment has not yet gone through independent, peer-reviewed review, NeurologyLive reported. Both numbers matter together. A treatment can reduce agitation and still carry a higher burden of serious health events in a population this frail, and a family considering a similar trial should expect to hear both figures, not just the one about symptom improvement.
Who was actually eligible, and why that matters for your relative
LiBBY did not enroll a broad cross-section of people with dementia. Participants had to be hospice-eligible or meet one of two severity thresholds: a score of stage 6d on the Functional Assessment Staging Test, or a score of 12 or higher on the Advanced Dementia Prognostic Tool, according to ClinicalTrials.gov. Both thresholds mark severe, late-stage disease, where a person has substantial functional and cognitive decline. That eligibility detail changes how the results apply to someone in an earlier stage of memory loss.
A person newly diagnosed with mild cognitive impairment or early-stage dementia was not part of this population, so the safety and efficacy numbers above describe late-stage disease specifically, not dementia broadly. Anyone comparing a family member's situation to LiBBY should check where that person falls on a staging scale before assuming the findings transfer. The severity of the population also explains part of the adverse event rate. People already at this stage of dementia, including many who are hospice-eligible, carry a higher baseline risk of medical complications independent of any study drug, which is part of why attribution of serious adverse events is a genuinely difficult judgment call for investigators to make.
Why consent worked differently in this trial
Because many participants had advanced cognitive impairment, they could not give informed consent themselves. The trial allowed consent from either the participant or a legally authorized representative, confirming that a substantial share of enrollees relied on a surrogate decision-maker, according to ClinicalTrials.gov. A legally authorized representative is typically a spouse, adult child, or court-appointed guardian with the legal standing to make medical decisions on someone else's behalf.
If you are approached about enrolling a relative in a similar dementia trial, expect the consent conversation to center on you rather than on the person with dementia, and expect the research team to walk through risks, including the possibility of serious adverse events, in detail before you sign anything. This arrangement is standard for research involving advanced dementia, since the population most affected by agitation symptoms is often the same population least able to weigh study risks independently. It is still worth asking the research team directly how they define a serious adverse event, how quickly they notify a representative if one occurs, and what triggers a participant's removal from the trial.
How the trial was run and funded
LiBBY was conducted at roughly ten U.S. sites, including Georgetown University, through the NIH-funded Alzheimer's Clinical Trials Consortium, a federally backed academic research network rather than a single independent lab, according to Georgetown University Medical Center.
The National Institute on Aging, part of the National Institutes of Health, funded the trial itself, and the Alzheimer's Association separately funded a follow-on open-label extension that let trial completers continue receiving the THC/CBD formulation, according to Pennington Biomedical Research Center. Running through a multi-site federal consortium matters because it means the study followed a shared protocol and oversight structure across all participating sites rather than each site setting its own rules. For a family evaluating whether to join a dementia trial, checking who funds it and which research network runs it is a reasonable first question, since it indicates the level of institutional oversight behind the enrollment and consent process.
What's still missing before drawing firm conclusions
The results discussed here are topline findings presented at a medical conference in July 2026, not yet published in a peer-reviewed journal, and the official ClinicalTrials.gov results record had not been updated to include them as of that presentation, according to ClinicalTrials.gov. Conference presentations typically precede full peer review, during which outside experts scrutinize the study's methods and the investigators' interpretation of events like the serious adverse events reported here.
That gap matters most for the safety data specifically, since the investigators' conclusion that none of the serious adverse events were drug-related has not yet been independently verified. Anyone using LiBBY as a reference point for a current or upcoming trial should treat the efficacy number as promising and the safety attribution as provisional until a peer-reviewed paper is available.
Frequently Asked Questions
Can someone with early-stage dementia use what LiBBY found to guide their own treatment decisions?
Not directly. Eligibility required late-stage disease, measured by hospice status or specific severity scores, so the results describe advanced dementia rather than early-stage memory loss.
Who actually signs the consent form if a trial participant has advanced dementia?
In LiBBY, either the participant or a legally authorized representative, often a spouse, adult child, or guardian, could provide consent, since many enrollees could not consent for themselves.
Is the THC/CBD formulation from LiBBY approved for use outside a trial?
The research packet does not establish any approval status; the reported results are topline conference findings, not yet published in a peer-reviewed journal.
You Might Also Like
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: Research Participation Questions for Adults With Memory Concerns
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: Research Participation Questions for Adults With Memory Concerns
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: Safety and Monitoring Questions for People With Early Alzheimer’s
